- Targeted Therapy
Global head and neck cancer treatment market valued at USD 2,481.6 million in 2022 and expected to grow at 9.3% CAGR over the forecast period. Head and Neck Cancer refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3–5% of all cancers in the US and are common in men and people over the age of 50. These cancers are easily preventable and can be treated if diagnosed early. The most common causes of Head and Neck Cancer are tobacco and alcohol use, and nowadays, Human Papilloma Virus (HPV) has also emerged as an important risk factor. Head and Neck Cancer usually begins in the squamous cells often referred to as squamous cell carcinomas of the head and neck, for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinoma. Head and Neck Cancer is common in several regions of cancer in the world. The annual incidence of head and neck cancers worldwide is more than 550,000 cases each year. According to Global Cancer Observatory (GLOBOCAN), the incidence of Head and Neck Cancer continues to rise and is anticipated to increase by 30% by 2029. A Rise in the number of risk factors such as the growth of cigarette smokers and alcohol & tobacco consumption is further anticipated to fuel the growth of the global head & neck cancer drugs market. Other factors such as the aging population, large oncology research funding, unmet medical requirements, increased market competition, better regulatory framework, aging population, and increasing government aid are all contributing to the global head and neck cancer market's growth. Despite these factors, there are still concerns about the head and neck cancer industry. The high cost of therapy, the negative effects of current treatment options, the absence of healthcare coverage, and the bad healthcare system in low- and middle-income countries may hinder the Head and Neck Cancer Treatment market growth.
Head and Neck Cancer Treatment Market Key Developments:
The Head and Neck Cancer Alliance (HNCA) and PDS Biotechnology Corporation formed a partnership in May 2021. This collaboration aims to increase awareness of new and developing treatment options for people who have been diagnosed with HPV-related head and neck cancer, including clinical studies that are currently being conducted.
Tipifarnib (Kura Oncology) was designated as a Breakthrough Therapy by the Food and Drug Administration (FDA) in February 2021 for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma who have a variant allele frequency greater than or equal to 20% after platinum-based chemotherapy
Fastest Growing Market
The increase in the number of cigarette smokers, and alcohol & tobacco consumption is further anticipated to fuel the growth of the global head & neck cancer drugs market. Human Papilloma Virus has also emerged as a risk factor. an estimated 75% of Head and Neck Cancers are caused by alcohol and cigarette intake. Cancer will be the cause of mortality, accounting for over 10 million fatalities, or one in six deaths. According to National Center for Biotechnology Information, nonsurgical therapies were the most preferred treatment option for HNC patients by physicians instead of surgical treatment being first-line treatment due to COVID-19-specific multilevel risks to HNC patients. Therefore, demand for nonsurgical therapeutics such as chemotherapy, immunosuppressive, and targeted therapy increased during the COVID-19 pandemic.
The Global market value of head and neck cancer treatment market was valued at USD 2,481.6 million in the year 2022.
The head and neck cancer treatment market is expected to grow at a significant CAGR of 9.3% from 2023 to 2029.
The leading players in the global Head and Neck Cancer Treatment Market are Eli Lilly and Company, Merck & co. Inc., Takeda Pharmaceutical Company Ltd., Coherus BioSciences, Teva Pharmaceutical Industry, Hoffman La-Roche, Astra Zeneca, Clinigen group plc, Bristol-Myers Squibb Company, Sanofi, Adaxic Inc, Pfizer, Novartis, Medtronics.